Andere talen Regen BioPharma, Inc. OTC Markets

Aandelen

RGBPP

US75886M4096

Vertraagde tijd OTC Markets Andere beurzen 19:28:14 17-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,5 ^USD	+48,51%		+19,05%	-36,40%

24/04	Regen BioPharma, Inc. Rapporteert de winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 31 maart 2024	CI
09/02	Regen Biopharma, Inc. Dient een voorlopige patentaanvraag in voor het versnellen van hematopoëtische reconstitutie na een verwonding of chronische pathologie door toediening van van stamcellen afgeleide endotheelprogenitorcellen of endotheelcellen	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Regen BioPharma : Material Event - Form 8-K	29/04
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	24/04
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	09/02
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	05/02
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	19/01
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	20/11
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	14/11
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	25-10-23
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	18-10-23
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	20-09-23
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	19-09-23
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding	12-09-23
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	08-08-23
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	25-07-23
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18-04-23
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	07-02-23
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23-01-23
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	19-01-23
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	19-01-23
Regen BioPharma, Inc. Announces Board Appointments	07-12-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Regen BioPharma, Inc. OTC Markets

Aandelen

RGBPP

US75886M4096

Andere talen

Filters